Semaglutide in Nonalcoholic Fatty Liver Disease
NCT05813249 on ClinicalTrials.gov · last registry update 2024-04-02
An unusually large phase 4: 180 participants, more than double the 75 typical for the stage. The sponsor logged completion for 15 February 2024. Primary outcome, as filed: NAFLD regression. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Zagazig University
- Sponsor type
- Other Gov
- Enrollment
- 180
- Started
- 2023-02-15
- Primary completion
- 2024-02-15 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
NAFLD regression
Conditions studied
Non-alcoholic Fatty Liver Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.